Netenax (Netilmicin)

Netilmicin, the active ingredient in Netenax, binds to the bacterial 30S ribosomal subunit. This binding interferes with the initiation of protein synthesis and causes misreading of messenger RNA, leading to defective proteins and rapid bacterial cell death.

The dosing regimen for Netenax is determined by the prescribing clinician based on the severity of the infection, patient age and ocular condition. The prescriber will specify the number of drops, frequency and duration of therapy on the prescription label.

Safety data for netilmicin in pregnancy and lactation are limited. Netenax should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.

To order Netenax, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Netenax (netilmicin) offers broad‑spectrum activity against many Gram‑negative and some Gram‑positive ocular pathogens, similar to other aminoglycosides such as tobramycin. Compared with fluoroquinolone eye drops, netilmicin may have a lower risk of resistance development but requires careful monitoring for ototoxicity and nephrotoxicity if systemic absorption occurs.

Netenax should be stored at room temperature, below 25 °C, in its original container. Protect the product from light and moisture, and keep the cap tightly closed when not in use. Do not freeze the solution.

Netenax is applied as eye drops. The prescribed number of drops is placed into the lower conjunctival sac of the affected eye(s) at the frequency indicated by the prescriber, typically avoiding contact with the tip of the bottle to maintain sterility.

Serious adverse events, although rare, include corneal ulceration, severe allergic reactions such as swelling or rash around the eye, and potential vision loss. Patients should seek immediate medical attention if they experience worsening pain, loss of vision, or signs of a severe allergic response.

Netenax is contraindicated in individuals with a known hypersensitivity to netilmicin, other aminoglycosides, or any component of the formulation. It should also be avoided in patients with active ocular surface disease that could increase systemic absorption unless specifically directed by a clinician.